Dr. Evelyn Cantillo, MD

Dr. Cantillo practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Cantillo's NPI, 1336464734, was assigned on March 29, 2010. Dr. Cantillo graduated from Albert Einstein College of Medicine in 2010. Dr. Cantillo's New York license number on file is 301841.

Dr. Cantillo's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Cantillo's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Cantillo to 2 more clinical labs, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cantillo practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Cantillo's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Cantillo is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Cantillo's licenses on file in 3 states: New York, Vermont and Rhode Island.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Cantillo treats.

CMS data shows 206 Medicare services from Dr. Cantillo across 7 procedure codes in 2024, for 131 Medicare patients. Medicare paid $18,648 for them. Every service was in an office.

CMS counts 131 Medicare patients who saw Dr. Cantillo in 2024. The largest group is 65 to 74, with 61 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cantillo's median patient age at 65, with 98% women.

In 2024, Dr. Cantillo wrote 114 Medicare Part D claims for 33 patients. 77% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $272 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Cantillo for performance year 2024, reported through an alternative payment model (APM). Dr. Cantillo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cantillo as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 31 papers to Dr. Cantillo, published from 2011 to 2024. 2023 was the busiest year, with 8. The most frequent topics are Ovarian Neoplasms, Cell Line, Tumor and Genetic Counseling. Dr. Cantillo has published most often in Gynecol Oncol. Dr. Cantillo's most frequent co-authors are Eloise Chapman-Davis, MD, Kevin M. Holcomb, MD and Melissa Kristen Frey, MD.

Dmand AI links Dr. Cantillo to 4 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Ovarian Epithelial and Carcinosarcoma. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 16 general payments to Dr. Cantillo from 7 drug and device companies from 2016 to 2025. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 93% of the total. GlaxoSmithKline, LLC. paid the most, $75,000.

Dr. Cantillo graduated from Albert Einstein College of Medicine in 2010.

Dr. Cantillo is in network with 18 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.